Skip to main content
Rapid Reactions
SABCS 2023 HR+/HER2-

Primary Analysis of HER2CLIMB-02: Addition of Tucatinib to Trastuzumab Emtansine in Previously Treated Patients with HER2-Positive Metastatic Breast Cancer

Videos - Rapid Reactions, Breast Cancer
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, MA
Dr Tolaney of Dana-Farber Cancer Institute reviews data on HER2CLIMB-02 and contributes future considerations of tucatinib in the metastatic HER2-positive breast cancer setting.
Related Items
HER2 Heartbreak? Understanding the Management of Cardiotoxicity From Trastuzumab in HER2-Positive Breast Cancer
JHOP - June 2026 Vol 16, No 3 published on January 21, 2026 in Symptom Management Overview, Breast Cancer, Targeted Therapies
Response to Alectinib in Refractory Breast Cancer With an EML4-ALK Rearrangement
JHOP - December 2025 Vol 15, No 6 published on September 29, 2025 in Case Reports, Breast Cancer, Tyrosine Kinase Inhibitor, Targeted Therapies
Simvastatin-Induced Rhabdomyolysis Potentially Triggered by Palbociclib Inhibition of CYP3A4: A Case Report
JHOP - February 2026 Vol 16, No 1 published on September 19, 2025 in Case Reports, Adverse Events, Drug–Drug Interaction, Breast Cancer
Highly Effective Treatment for Bone-Only Signet Ring Cell Breast Cancer With Ribociclib, Fulvestrant, and Denosumab: A Case Study
JHOP - October 2025 Vol 15, No 5 published on July 17, 2025 in Case Reports, Breast Cancer, Chemotherapy
Incidence of Febrile Neutropenia in Patients With Grade 3 or 4 Neutropenia Who Are Receiving Palbociclib
JHOP - October 2024 Vol 14, No 5 published on October 11, 2024 in Original Research, Adverse Events, Breast Cancer, CDK4/6 Inhibitors, Oncology Pharmacy Programs/Protocols
Exemestane Treatment in a Male Patient With Concurrent Breast and Prostate Cancers: A Case Report
JHOP - August 2024 Vol 14, No 4 published on August 2, 2024 in Case Reports, Breast Cancer, Prostate Cancer
Evaluation of Pharmacist-Driven Approach to Monitoring for Neutropenia Related to CDK4/6 Inhibitors in Women With Advanced Breast Cancer
JHOP - June 2024 Vol 14, No 3 published on May 23, 2024 in Practical Issues in Pharmacy Management, Oncology Pharmacy Programs/Protocols, Breast Cancer, CDK4/6 Inhibitors, Adverse Events
Real-world Outcomes Following Initiation of Abemaciclib in Patients With Brain Metastases Secondary to HR+/HER2- Metastatic Breast Cancer
Hope S. Rugo, MD
Videos published on February 9, 2024 in Rapid Reactions, Breast Cancer
INAVO120 Phase III Study: Treatment of Patients With PIK3CA-mutant, HR+/HER2- Locally Advanced or Metastatic Breast Cancer With Invavolisib in Combination With Palbociclib and Fulvestrant
Hope S. Rugo, MD
Videos published on February 7, 2024 in Rapid Reactions, Breast Cancer
Abemaciclib and NSAI for 1L Treatment of HR+/HER2- Advanced Breast Cancer: Long-term Survival Data Reported
Sara M. Tolaney, MD, MPH
Videos published on February 6, 2024 in Rapid Reactions, Breast Cancer